Pharma procurement teams are sitting on a powerful risk signal—and most are ignoring it.
Paragraph IV filings—those patent-challenge notices tied to generic and biosimilar launches—aren’t just a legal footnote. They’re a forward-looking map of where pr…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re a pharma executive, investor, or in-house counsel, you already know the headline: “patent term” is not the same thing as “effective protection…

Drug patent expiry dates aren’t just legal milestones—they’re revenue inflection points. Yet too many commercial teams treat them like static calendar items instead of dynamic sales intelligence.
Here’s the agitation: when a patent clock runs down, the…

Sell the Line Before the Patent Breaks: A Business Development Playbook for Solid-Dose Equipment Suppliers
The most expensive mistake in pharma equipment sales isn’t pricing—it’s timing.
If you wait until a patent clock hits zero to start selling into …

The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/

The “Smarter Monopoly” Debate Is Here—and It’s About More Than Patents
Drug pricing isn’t just a policy argument anymore—it’s a design problem. And the design question at the center of today’s debate is deceptively simple: Should orphan drug exclusivit…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic LOE
Biologics don’t just “end.” They cliff.
Loss of Exclusivity (LOE) for biologics can arrive like a switch—suddenly, the market price resets…

The patent clock is ticking. But in pharma, time doesn’t always run out the way investors—and patients—expect.
Drug Patent Watch’s latest piece, “Squeeze the Patent: How Drug Companies Use Reformulation and New Indications to Outlast Generic Competitio…

Patients don’t ask “patent law questions.” They ask survival questions.
When someone types “Can I switch my medication?” or “Will my insurance cover the generic?” they’re not thinking about claim charts or priority dates. They’re thinking about side ef…

Evergreening isn’t a surprise—it’s a strategy.
For years, brand companies have used a familiar playbook: file incremental patents, tweak formulations, expand indications, and extend exclusivity windows just long enough to keep generic competition at ba…